Impact of HIV-1 Subtypes on CD4+ T-Cell Decline and Treatment Timing
Author Information
Author(s): Ng Oon Tek, Lin Li, Laeyendecker Oliver, Quinn Thomas C., Sun Yong Jiang, Lee Cheng Chuan, Leo Yee Sin
Primary Institution: Division of Infectious Diseases, Johns Hopkins School of Medicine
Hypothesis
Does the HIV-1 subtype influence the rate of CD4+ T-cell loss and time to antiretroviral therapy initiation?
Conclusion
Subtype CRF01_AE infected patients experienced a significantly higher rate of CD4+ T-cell loss and initiated treatment faster than those infected with non-CRF01_AE subtypes.
Supporting Evidence
- CRF01_AE infected patients had a mean 58 cells/mm3/year greater adjusted loss of CD4+ T-cells compared to other subtypes.
- The median time from estimated date of seroconversion to ART initiation was 1.8 years faster for CRF01_AE infected patients.
- 79% of CRF01_AE infected patients initiated ART compared to 47% of non-CRF01_AE infected patients.
Takeaway
Some types of HIV make people lose important immune cells faster and get treatment sooner than others.
Methodology
The study used multilevel mixed-effects models to analyze CD4+ T-cell decline and Kaplan-Meier survival methods for time to ART initiation.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific demographic of participants.
Limitations
The study was limited to a specific population in Singapore and may not be generalizable to other regions.
Participant Demographics
The cohort consisted of 54 patients, predominantly male (98%) and of Chinese ethnicity (96%), with a median age of 30.6 years.
Statistical Information
P-Value
0.027
Confidence Interval
95% CI: 7 to 109
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website